LK 423

Drug Profile

LK 423

Alternative Names: LEK 423

Latest Information Update: 23 Mar 2007

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator LEK
  • Developer Fujimoto Pharmaceutical
  • Class Dipeptides; Phthalimides; Small molecules
  • Mechanism of Action Interleukin 10 stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Ulcerative colitis

Most Recent Events

  • 23 Mar 2007 Discontinued - Preclinical for Ulcerative colitis in Japan (unspecified route)
  • 23 Dec 2002 LEK has been acquired by Novartis
  • 27 Jan 2000 Preclinical development for Ulcerative colitis in Japan (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top